Tags

Type your tag names separated by a space and hit enter

Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk.
Climacteric. 2022 08; 25(4):362-368.C

Abstract

The threat that women may develop breast cancer is the major reason why both physicians and women are afraid to use menopausal hormone therapy (MHT). The fear pertains to estrogen-progestin replacement therapy (EPRT) as estrogen-alone replacement therapy has no, or even a reduced, breast cancer risk. We reviewed the way breast cancer risk with EPRT was reported in some major publications since 2002 and tried to put the use-risk association in context. We hope this will make it easier for the physician and the menopausal woman to understand the risk involved and allow more confident and more informed decision-making regarding MHT use. We conclude that there are five interrelated reasons why physicians and women should no longer be afraid of the breast cancer risk with EPRT. We submit that breast cancer related to EPRT use is rare because the risk is very low; the reported increase in breast cancer risk with EPRT is not relevant to current practice; modifiable lifestyle factors, not EPRT, are the real risks for breast cancer; breast cancer-specific mortality is reduced in women who develop breast cancer while on EPRT; and avoiding MHT use when indicated puts a woman in harm's way.

Authors+Show Affiliations

Section of Reproductive Medicine, Department of Obstetrics and Gynecology, St. Luke's Medical Center - Quezon City, Quezon City, Philippines.Section of Reproductive Medicine, Department of Obstetrics and Gynecology, St. Luke's Medical Center - Quezon City, Quezon City, Philippines.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

35147073

Citation

Tan, D A., and A R B. Dayu. "Menopausal Hormone Therapy: Why We Should No Longer Be Afraid of the Breast Cancer Risk." Climacteric : the Journal of the International Menopause Society, vol. 25, no. 4, 2022, pp. 362-368.
Tan DA, Dayu ARB. Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk. Climacteric. 2022;25(4):362-368.
Tan, D. A., & Dayu, A. R. B. (2022). Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk. Climacteric : the Journal of the International Menopause Society, 25(4), 362-368. https://doi.org/10.1080/13697137.2022.2035711
Tan DA, Dayu ARB. Menopausal Hormone Therapy: Why We Should No Longer Be Afraid of the Breast Cancer Risk. Climacteric. 2022;25(4):362-368. PubMed PMID: 35147073.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk. AU - Tan,D A, AU - Dayu,A R B, Y1 - 2022/02/11/ PY - 2022/2/12/pubmed PY - 2022/7/12/medline PY - 2022/2/11/entrez KW - Menopausal hormone therapy KW - attributable risk KW - baseline risk KW - breast cancer KW - categories of risk SP - 362 EP - 368 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric VL - 25 IS - 4 N2 - The threat that women may develop breast cancer is the major reason why both physicians and women are afraid to use menopausal hormone therapy (MHT). The fear pertains to estrogen-progestin replacement therapy (EPRT) as estrogen-alone replacement therapy has no, or even a reduced, breast cancer risk. We reviewed the way breast cancer risk with EPRT was reported in some major publications since 2002 and tried to put the use-risk association in context. We hope this will make it easier for the physician and the menopausal woman to understand the risk involved and allow more confident and more informed decision-making regarding MHT use. We conclude that there are five interrelated reasons why physicians and women should no longer be afraid of the breast cancer risk with EPRT. We submit that breast cancer related to EPRT use is rare because the risk is very low; the reported increase in breast cancer risk with EPRT is not relevant to current practice; modifiable lifestyle factors, not EPRT, are the real risks for breast cancer; breast cancer-specific mortality is reduced in women who develop breast cancer while on EPRT; and avoiding MHT use when indicated puts a woman in harm's way. SN - 1473-0804 UR - https://www.unboundmedicine.com/medline/citation/35147073/Menopausal_hormone_therapy:_why_we_should_no_longer_be_afraid_of_the_breast_cancer_risk. DB - PRIME DP - Unbound Medicine ER -